Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for eosinophilic chronic rhinosinusitis with nasal polyps
ACTRN12624000716561Phase 2Recruiting
- Sponsor
- Griffith University
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic chronic rhinosinusitis (ECRS), sponsored by Griffith University. Primary endpoint: Histopathological eosinophilic count. Started Aug 2024; status: recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)eosinophilic chronic rhinosinusitis (ECRS)
Beyond the preview
Go deeper on ACTRN12624000716561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000716561.